IN8bio, Inc. Presents New Preclinical Data on INB-619 at ACR Meeting
1分未満で読めます
On October 27, 2025, IN8bio, Inc. announced new preclinical data for its INB-619 program at the ACR Convergence Meeting.
Key Highlights:
- INB-619 shows efficacy comparable to FDA-approved TCEs with minimal cytokine release.
- First pan-γδ T cell engager to expand multiple γδ T cell subsets for target elimination.
- Achieved complete B cell depletion in both healthy and SLE donor samples.
- Potential for higher doses and deeper B cell depletion with improved safety profile.
- Targets γδ TCR, reducing toxicities associated with conventional TCEs.
Original SEC Filing: IN8BIO, INC. [ INAB ] - 8-K - Oct. 27, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.